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Mitochondrial dysfunctionNormal differentiated cells rely primarily on mitochondrial oxidative phosphorylation to produce adenosine
triphosphate (ATP) to maintain their viability and functions by using three major bioenergetic fuels: glucose,
glutamine and fatty acids. Many cancer cells, however, rely on aerobic glycolysis for their growth and survival,
and recent studies indicate that some cancer cells depend on glutamine as well. This altered metabolism in
cancers occurs through oncogene activation or loss of tumor suppressor genes in multiple signaling pathways,
including the phosphoinositide 3-kinase and Myc pathways. Relatively little is known, however, about the
role of fatty acids as a bioenergetic fuel in growth and survival of cancer cells. Here, we report that human
glioblastoma SF188 cells oxidize fatty acids and that inhibition of fatty acid β-oxidation by etomoxir, a
carnitine palmitoyltransferase 1 inhibitor, markedly reduces cellular ATP levels and viability. We also found
that inhibition of fatty acid oxidation decreases nicotinamide adenine dinucleotide phosphate (NADPH) levels
and the reduced glutathione (GSH) content and elevates intracellular reactive oxygen species. These results
suggest that modulation of fatty acid oxidation controls the NADPH level. In the presence of reactive oxygen
species scavenger tiron, however, ATP depletion is prevented without restoring fatty acid oxidation. This
suggests that oxidative stress may lead to bioenergetic failure and cell death. Our work provides evidence that
mitochondrial fatty acid oxidation may provide NADPH for defense against oxidative stress and prevent ATP
loss and cell death. This article is part of a Special Issue entitled: Bioenergetics of Cancer.ergetics of Cancer.
+1 978 671 1611.
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
Otto Warburg [1] ﬁrst described the high rate of glucose
conversion to lactate in cancer cells, compared to their normal
counterparts, despite the presence of ample oxygen, known as the
Warburg effect, more than 80 years ago. It is now recognized that this
altered cellular metabolism is a result of oncogenic transformation
and has emerged as a hallmark of cell transformation to a cancer
phenotype [2,3]. Genetic alterations in multiple signaling pathways,
predominantly the PI3K–AKT pathway and Myc mediated pathways,
allow cancer cells to constitutively take up and metabolize glucose
and glutamine in excess of their bioenergetic and biosynthetic needs
[3–5].
In normal differentiated cells, mitochondrial respiration burns
glucose, fatty acids and amino acids from dietary sources with oxygen,
through oxidative phosphorylation, to produce usable energy in the
form of ATP. Mitochondrial oxygen consumption reﬂects both theactivities of the electron transport chain (ETC) and the tricarboxylate
(TCA) cycle within the mitochondria. It also reﬂects the availability
and types of bioenergetic substrates supplied from the cytosol, that is,
the cellular context in which mitochondria function. Unlike mito-
chondria in normal differentiated cells which function as primarily as
bioenergetic organelle, in addition to producing ATP, mitochondria of
cancer cells as well as proliferating cells are also biosynthetic
organelles for lipid and amino acid production, both of which are
needed to support cellular replication [4]. Bioenergetic and biosyn-
thetic activities are coordinated through the shared TCA cycle in the
mitochondria. Bioenergetically, the TCA cycle extracts energy from
substrates into the reducing equivalent of NADH, which is then
oxidized in the electron transport chain, reducing molecular oxygen
to water and fueling oxidative phosphorylation for ATP production.
Biosynthetically, TCA cycle intermediaries such as citrate and malate
exit the cycle to provide precursors for lipid and amino acid
biosynthesis resulting in a truncated TCA cycle. ATP production and
biosynthesis of building blocks required to sustain cellular function
and cell viability are functionally coordinated by interlocking
regulatory mechanisms that control the rates of both the electron
transport (oxygen consumption) and the TCA cycle. In addition, the
727L.S. Pike et al. / Biochimica et Biophysica Acta 1807 (2011) 726–734TCA cycle can also produce the reducing equivalent NADPH, a potent
non-enzymatic antioxidant in the mitochondria that is crucial to cell
viability [3].
During mitochondrial respiration, electrons leak out of the electron
transport chain and generate ROS. ROS include sequential intermediates
generated by univalent reductions of molecular oxygen through
stepwise electron transfer from the superoxide radical (O2−) to
hydrogen peroxide (H2O2) and then the hydroxyl radical (OH), which
can ﬁnally be reduced to water. ROS production increases when
excessive nutrients become available to the cells, and these ROS can
either promote cell proliferation or potentially cause oxidative damage.
Fatty acids are synthesized from excessive dietary glucose and
stored as lipids (triglyceride) in the cell, predominantly in adipose and
liver tissues. They can be released into the blood stream and taken up
and utilized by other tissues, including skeletal and cardiac muscles
where fatty acids are degraded in the mitochondria by β-oxidation
and oxidative phosphorylation to produce ATP. In contrast to normal
cells, de novo fatty acid synthesis occurs at high rates in tumor tissues
[6,7].
In this study, we investigated the role of fatty acid oxidation in
cancer cell metabolism, growth and survival. We found that an
essential function of fatty acid oxidation in cancer cells is to provide
the reducing equivalent NADPH to maintain the antioxidant system
against oxidative stress and thereby promote cell viability.
2. Material and methods
2.1. Reagents
Etomoxir, FCCP, dihydroethidine, tiron, sodium palmitate, glucose
and L-glutamine were obtained from Sigma (St. Louis, MO, USA).
Oligomycin was obtained from EMD (San Diego, CA, USA). Fatty acid
ultra-free bovine serum albumin (BSA) was obtained from Roch
Diagostics (Indianapolis, IN, USA). All compounds were prepared
according to the manufacturers' instructions.
2.2. Cell line and cell culture
Human SF188 glioblastoma cells were obtained from the Univer-
sity of California at San Francisco Brain Tissue Bank. The cells were
initially maintained MEM containing 5.5 mM glucose and 2 mM
glutamine (Invitrogen, Carlsbad, CA, USA) supplemented with 10%
fetal bovine serum (FBS, Hyclone, Logan, UT, USA) as recommended.
When we adapted them into DMEM (Invitrogen) containing 25 mM
glucose and 6 mM L-glutamine supplemented with 10% FBS, the cells
adopted a much more rapid proliferation rate and a much more
oxidative metabolic phenotype, which will be published elsewhere.
The rapid growing and oxidative SF188 cells were used in this study.
C2C12 myoblast was obtained from American Type Culture Collection
(Manassas, VA 20108). They were maintained in DMEM containing
25 mM glucose, 4 mM L-glutamine and 1 mM pyruvate supplemented
with 10% FBS. Both cell lines were maintained in a humidiﬁed
incubator at 37 °C/10% CO2 until they reached ~70%–80% conﬂuence
and subcultured into T ﬂasks or plated on microplates for assays.
Growth medium was refreshed every two days.
C2C12 myoblasts were differentiated into myocytes prior to an
assay. They were plated at 1.0×104 cells/well and incubated for
48 hours prior to switching to differentiation medium, which was
DMEM supplement with 1% horse serum, for 3 days allowingmyocyte
differentiation.
2.3. Measurement of cellular oxygen consumption rate and extracellular
acidiﬁcation rate using the XF Extracellular Flux Analyzer
Cellular oxygen consumption rate (OCR) and extracellular acidi-
ﬁcation rate (ECAR) were used to monitor fatty acid oxidation andglycolysis in real time when the appropriate substrates were added to
or included in assaymedium as indicated in the relevant experiments.
Details of assaying glucose, glutamine and fatty acid metabolism will
be published elsewhere.
Oxygen consumption rate and extracellular acidiﬁcation rate
measurements were performed using the Seahorse XF24 Extracellular
Flux Analyzer as described [8]. SF188 cells were plated in XF24 V7 cell
culture plates (Seahorse Bioscience, North Billerica, MA, USA) at
2.0×104 cells/well and incubated for 24 hours in a 37 °C/10% CO2
incubator. Cells were equilibrated with bicarbonate-free low buffered
DMEM medium without any supplement or supplemented with
glucose and/or glutamine as indicated in each experiment and
incubated in a 37 °C non CO2 incubator for 45 minutes immediately
before XF assay. Substrates or perturbation compounds were
prepared in the identical assay medium as in the corresponding
well and were injected from the reagent ports automatically to the
wells at the time as indicated.
2.4. Preparation of palmitate–BSA conjugates
Palmitate was conjugated to BSA when both components were
solubilized. Brieﬂy, odium palmitate was solubilized in 150 mM
sodium chloride by heating up to 65 °C in a water bath. BSA was
dissolved in phosphate buffered saline (PBS) (Invitrogen) and
warmed up to 37 °C. with continuous stirring. Solubilized palmitate
was added to BSA at 37 °C with continuous stirring. The conjugated
palmitate–BSA was aliquoted and stored at −20 °C. Palmitate–BSA
conjugate was used to assess oxidation of exogenous fatty acid.
Detailed protocol will be published elsewhere.
2.5. Proliferation assay
The number of viable cells per well were determined after trypan
blue staining. Cells were plated at 1×105 cells/well in 12-well tissue
culture plate. After 24, 48 or 72 hours, cells were trypsinized and
suspended in medium. Cells were counted using a ViCell Counter
(Beckman Coulter, Fullerton, CA, USA).
2.6. Cellular ATP measurement
Luminescence was used to determine the relative ATP level of cells
exposure to etomoxir. Cells were plated in white 96well tissue culture
microplates at 2×104 cells/well and incubated in 37 °C/10% CO2
incubator for 24 hours. The cells were exposed to etomoxir in
bicarbonate-free DMEM medium containing 25 mM glucose and
6 mM glutamine for 45 minutes in a 37 °C non CO2 incubator before
being assayed with CellTiter-Glo® Luminescent Cell Viability Assay
(Promega, Madison, WI, USA). Luminescent intensity from each well
was measured using a FLUOstar Optima plate reader (BMG Labtech,
Durham, NC, USA).
2.7. Calcein AM cell viability assay
The relative viability was determined using the Calcein AM assay.
Cells were plated in black 96 well tissue culture microplates at 2×104
cells/well and incubated in the 37 °C incubator for 24 hours in parallel
with the cells for ATP assay. Cells were treated with etomoxir in the
identical assay medium for the ATP assay for 45 minutes, and the
relative viabilities were analyzed using the cell-permeable ﬂuoro-
chrome calcein AM (Invitrogen). Cellswere incubatedwith1 μMCalcein
AM for 30 minutes before analysis on a FLUOstar Optima plate reader.
2.8. Measurement of intracellular ROS
Fluorescence image analysis was used to determine the relative
levels of ROS in response to etomoxir. Cells were harvested and
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(Invitrogen) supplemented with 25 mM glutamine and 6 mM L-
glutamine. They were and treated with 1 mM etomoxir for 25 min-
utes. The relative levels of intracellular ROS were analyzed using the
cell-permeable superoxide-sensitive ﬂuorochrome dihydroethidine.
Cells were incubated with dihydroethidine (10 μM) for 15 minutes at
37 °C before analysis using a BD FACSCanto II ﬂow cytometry (BD
Biosciences, San Jose, CA, USA).
2.9. Cellular GSH assay
GSH sensing luminescence was used to determine the relative
glutathione level of cells exposed to etomoxir. Cells were plated in
white 96 well tissue culture microplates at 4 x 103 cells/well and
incubated in 37 °C/10% CO2 incubator for 24 hours. The cells were
exposed to etomoxir in bicarbonate-free DMEM medium containing
25 mMglucose and 6 mMglutamine for 30 minutes in a 37 °C non CO2
incubator and the relative levels of glutathione were analyzed using
GSH-Glo™ Glutathione Assay (Promega). Luminescent intensity of
each sample was measured using a FLUOstar Optima plate reader.
2.10. Measurement of cellular NADPH
NADPH sensing ﬂuorescence was used to determine NADPH level
of cells treated with etomoxir. Cells were harvested and suspended
at 4×106 in DMEM supplemented with 25 mM glutamine and 6 mM
L-glutamine. They were treated with etomoxir and lysed before
NADPH detection. NADPH cycling reaction was performed using an
Amplite™ Fluorimetric NADPH Assay (AAT Bioquest, Sunnyvale, CA,
USA) before analysis on a FLUOstar Optima plate reader.
2.11. Statistical analysis
Data are presented as mean±SD. Statistical analysis was
performed using Student's T-test, with pb0.05 considered signiﬁcant.
3. Results
3.1. Fatty acid oxidation in SF188 glioblastoma cells
Fatty acids taken up from extracellular environment or released
from intracellular lipid storage in the cytoplasm of normal cells canA B
Fig. 1. Human glioblastoma SF188 oxidizes endogenous fatty acid. Oxidation of endogen
Extracellular Flux Analyzer. A. Illustration of fatty acid oxidation and synthesis in mitochond
the TCA cycle generating NADH that is oxidized by the ETC consuming oxygen or producing
glutamine. Glucose is converted to pyruvate via a series of catabolic reactions. Pyruvate is eith
enters the TCA cycle and exit as citrate, which is then exported to cytosol for the synthesis o
and exits as malate and citrate into the cytosol for fatty acid synthesis. B. Glucose (25 mM
supplemented in assay medium. C. Etomoxir (ETO, 1 mM) was added to the cells after b
glutamine. The arrows indicate the time when ETO was added to the cells.enter the mitochondria for β-oxidation. Fatty acids are converted to
Acyl CoA, which is then transported into the mitochondria by the long
chain fatty acid transporter CPT-1. Once inside the mitochondria, Acyl
CoA is degraded to Acetyl CoA via β-oxidation. Acetyl CoA enters the
TCA cycle where it is further broken down to CO2, producing the
reducing equivalent NADH which fuels oxidative phosphorylation or
the reducing equivalent NADPH (Fig. 1A). Early studies indicate that
cancer cells can take up and oxidize exogenous fatty acids from the
extracellular environment [9,10]. Whether cancer cells perform
oxidation of endogenous fatty acids, which they synthesize at a high
rate, remains unclear. Monitoring cellular oxygen consumption
provides an alternative and easy means to assess oxidation of both
endogenous and exogenous fatty acids. Oxidation of exogenous fatty
acid can be assessed bymonitoring cellular oxygen consumption upon
addition of fatty acid such as palmitate. We observed increased OCR of
the cells in medium containing 5.5 mM glucose and 0.5 mM carnitine
upon addition of palmitate (200 μM), which was blunted by
subsequent etomoxir addition, suggesting that they can take up and
oxidize exogenous fatty acids (data not shown). Importantly,
oxidation of intracellular (endogenous) fatty acids by cells can be
determined by monitoring the OCR of cells in medium containing no
exogenous glucose or glutamine and by using speciﬁc inhibitors of
fatty acid oxidation.
To determine if SF188 cells oxidize endogenous fatty acid, we ﬁrst
determined the oxygen consumption rate of the cells in medium
containing no exogenous substrate (glucose or glutamine). We found
that these cells consumed signiﬁcant amounts of oxygen, ~250 pmol/
min, (Fig. 2A), in the absence of exogenous substrate suggesting
oxidation of endogenous substrate. Supplementing glutamine in assay
medium, regardless of presence or absence of glucose, raised the OCR
by about 150 pmol/min, again conﬁrming that glutamine is oxidized
by the cells (Fig. 1B).
Transport of long chain fatty acids into mitochondria through CPT-
1 on the mitochondrial outer membrane is the main controlling step
of fatty acid oxidation. Therefore, blocking the transport of fatty acids
into the mitochondria (in the absence of exogenous substrates)
should decrease the oxygen consumption rate of the cells if
endogenous fatty acid is oxidized. This can be accomplished with
etomoxir, which binds irreversibly to the CPT-1 transporter and
inhibits fatty acid oxidation. To conﬁrm that oxidation of endogenous
fatty acid contributed to the observed oxygen consumption rate in the
absence of exogenous substrates, we assessed whether etomoxirC
ous fatty acid was determined by measuring oxygen consumption rate using XF24
ria. Fatty acids enter the mitochondria for β-oxidation to Acetyl CoA. Acetyl CoA enters
NADPH as indicated. Endogenous fatty acids can be synthesized de novo from glucose or
er converted to lactate or enters mitochondria to be converted to Acetyl CoA. Acetyl CoA
f fatty acids. Glutamine enters the TCA cycle after conversion to α-ketoglutarate (α-KG)
) plus glutamine (6 mM), glutamine (6 mM), glucose (25 mM) or no substrate were
aseline measurement in assay medium containing no exogenously added glucose or
AB
Fig. 2. Glutamine as the carbon source for endogenous fatty acids. A. Glutamine is
required for cell growth and survival. Cells were cultured in DMEM medium
supplemented with glucose (25 mM) plus glutamine (6 mM), glucose (25 mM) or
glutamine (6 mM) in a 12-well microplate, and the number of viable cells under each
condition was determined at 24, 48 and 72 hours post plating. Mean±SD. (n=3;
*pb0.05). B. Eliminating glutamine from growth medium (glucose only) for 48 hours
led to decreased endogenous fatty acid oxidation in these cells. Cells were cultured in
DMEM medium supplemented with glucose (25 mM) plus glutamine (6 mM), glucose
(25 mM) or glutamine (6 mM) in an XF microplate for 48 hours. The growth medium
was replaced with assay medium containing no glucose or glutamine before measuring
oxygen consumption rate. The OCRs were normalized against the number of viable cells
being measured. Mean±SD. (n=3, pb0.001).
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the medium containing no glucose and no glutamine, and the oxygen
consumption by the cells was monitored. As shown in Fig. 2B,
etomoxir addition lowered the OCR to about 50% of the control. This
conﬁrmed that the cells indeed respired on endogenous fatty acids,
accounting for up to 1/3 of total cellular oxygen consumption when
glutamine was present. These data show that SF188 cells oxidize both
endogenous and exogenous fatty acids.
3.2. Glutamine as the carbon source for the synthesis of endogenous fatty
acid
Glucose-derived carbon is considered the primary source for de
novo fatty acid synthesis. The body converts excess dietary glucose to
fatty acids and store them as intracellular lipids in adipocytes as well
as hepatocytes. SF188 cells have been shown to depend on glutamine
for their growth and survival [11,12]. In addition to glucose, a fraction
of glutamine also contributes to fatty acid synthesis. First, we
determined cell proliferation and viability of SF188 cells grown in
medium containing glucose only, glutamine only or both glucose and
glutamine over a 72 hours period of time. Cell viability was monitored
every 24 hours and the number of viable cells was determined using
ViCell after removing the cells from themicroplates. The growth of the
cells over this 72 hour period was shown in Fig. 2A. The number of
viable cells and the viability of cells under all three growth conditions
were similar within 48 hours post plating, and signiﬁcant differences
in growth and viability were not observed until 72 hours. When
glucose was eliminated from the medium (glutamine only), cellproliferation slowed signiﬁcantly compared to the control cells at
72 hours; however, the cell viability was similar to the control. This
suggests that glucose contributes to cell growth but is not required for
cell survival and glutamine is sufﬁcient to sustain cell growth and
viability. In contrast, when glutaminewas eliminated from the growth
medium (glucose only), massive cell death was observed at 72 hours
(data not shown) resulting in fewer viable cells (Fig. 2A) suggesting
that glutamine is necessary for cell survival. This result is consistent
with glutamine addiction by SF188 cells reported previously [12]. The
number of viable cells and the viability of cells under all three growth
conditions were similar at 48 hours post plating.
Next, we examined the oxidation of endogenous fatty acid of cells
under these three growth medium conditions for 48 hours when they
display similar viability and growth rate. Cells were plated in medium
containing glucose only, glutamine only or both glucose and
glutamine and cultured for 48 hours in XF cell culture plates. The
growth medium was replaced with assay medium containing no
exogenous substrate before their oxygen consumption rates were
measured. Cells were removed from the microplate after the assay by
trypsin digestion and the number of viable cells was determined. The
OCRs of the cells under each condition were normalized using the
number of cells in each well. As shown in Fig. 2B, when glutaminewas
eliminated from the growth medium (glucose only), the oxygen
consumption rate of the cells was signiﬁcantly lower compared to that
of the cells grown in control medium. Interestingly, the oxygen
consumption rate of cells grown in medium containing no glucose did
not differ signiﬁcantly from the control cells suggesting that glucose
may not contribute signiﬁcantly to the intracellular fatty acids that
ﬂux into mitochondria for oxidation and/or that the presence of
glucose inhibits oxidative phosphorylation (the Crabtree effect). Fatty
acid oxidation was conﬁrmed again with the addition of etomoxir to
the cells. We found that the oxygen consumption rate was reduced to
a similar extent compared to the baseline rate of each group of cells
before etomoxir addition (data not shown) conﬁrming the occurrence
of endogenous fatty acid oxidation under all three growth conditions.
The decreased endogenous fatty acid oxidation in cells grown in
the absence of glutamine (glucose only) for 48 hours can be
interpreted as that the lowered endogenous fatty acid content in
the cells may lead to the reduced ﬂux of fatty acids for β-oxidation in
the mitochondria and/or the Crabtree effect. The ﬂow of carbon from
glutamine to fatty acids integrated with oxidation of endogenous and
exogenous fatty acids is illustrated in Fig. 1A. These results provide
indirect evidence suggesting that glutamine is involved in the de novo
synthesis of fatty acids which feed into mitochondrial β-oxidation in
SF188 cells.
3.3. Inhibition of fatty acid oxidation causes acute cellular ATP depletion
and massive cell death within 18 hours
Having established that SF188 cells oxidize fatty acids, both
endogenous and exogenous, we then investigated whether they
depend on fatty acid for their growth and survival. We took the
approach of pharmacologically inhibiting fatty acid oxidation using
etomoxir. Cells were treated with 1 mM etomoxir, the concentration
that causes maximal inhibition of fatty acid oxidation as determined
by acute exposure, for 18 hours in the standard growth medium, and
viability was examined microscopically and the number viable cells
were determined using ViCell after removing the cells from each well.
Oligomycin, an ATP synthase inhibitor, abolishes oxidative phosphor-
ylation and inhibits mitochondrial ATP production. The oligomycin
concentration (0.5 μM) that induces maximal decrease of OCR of the
cells during an acute exposure, was used as a control for inhibition of
mitochondrial ATP synthesis in the same experiment. We found that
etomoxir treatment induced massive cell death as observed micro-
scopically and reduced the number of viable cells to ~30% of the
control. This suggests that fatty acid oxidation is required for cancer
730 L.S. Pike et al. / Biochimica et Biophysica Acta 1807 (2011) 726–734cells survival. Oligomycin treatment only slightly reduced the cell
number (Fig. 3A) but did not have a signiﬁcant effect on the cell
viability (data not shown) suggesting that inhibition of oxidative
phosphorylation can be compensated for by an increase in glycolysis
to sustain cellular ATP level and cell viability in vitro where glucose
supply is ample.
We then investigated whether inhibition of fatty acid oxidation
impairs cellular ATP production, which might ultimately lead to cell
death, by measuring ATP levels in cells treated with etomoxir or
oligomycin. Fatty acid oxidation can produce ATP through mitochon-
drial oxidative phosphorylation, a process that is inhibited by the ATP
synthase inhibitor oligomycin. The cells were treated with etomoxir
(1 mM) and oligomycin (0.5 μM) respectively, for 45 minutes, prior to
ATP level measurement. As shown in Fig. 3B, the ATP level of the
etomoxir treated cells declined to approximately 50% of the control
cells. However, oligomycin treatment did not affect the ATP level
signiﬁcantly because of the compensatory increase in glycolysis as we
have shown previously [8]. The cells treated under both conditions
remained viable as determined by Calcein AM viability staining
(Fig. 3B).
We have shown previously that the ATP levels of cancer cells are
maintained during oligomycin treatment [8] as a result of a
compensatory increase in glycolysis rate in response to the increased
energy demand. We explored whether etomoxir inhibition of fatty
acid oxidation by the cells led to a compensatory increase in glycolysis
as does oligomycin by monitoring their ECAR during their exposure to
etomoxir or oligomycin. We observed an increase in glycolysis rate of
the cells in response to etomoxir although to a lesser extent than that
of oligomycin (Fig. 3C), suggesting that the ATP depletion by etomoxir
could not be completely accounted for by a moderate compensatory
increase in the glycolysis. These ﬁndings raised the possibility that
fatty acid oxidation may have additional roles beyond ATP synthesis
that indirectly impact cellular energy metabolism and viability.
3.4. NADPH deﬁciency induced by inhibition of fatty acid oxidation
results in oxidative stress and ATP depletion
Oxidative stress can promote tumorigenesis, cell proliferation or
cell death depending on the magnitude of stress and cellular context
[13,14]. It has been previously shown that cancer cells exhibit
elevated ROS [15,16] and can adapt their antioxidant system to
survive the increased oxidative stress. Excessive ROS can kill cancer
cells as well [17]. We suspected that etomoxir might kill the cells by
inducing severe oxidative stress. To test this, we analyzed intracellular
ROS levels etomoxir treated cells. Superoxide was measured by
dihydroethidine staining of the cells followed by ﬂow cytometry
analysis. Cells were harvested and suspended in PBS supplemented
with 25 mM glucose and 6 mM glutamine and then treated withA B
Fig. 3. Inhibition of fatty acid oxidation by etomoxir causes cell death and ATP depletion. A.
oligomycin (0.5 μM) for 18 hours. Mean±SD. (n=3; pb0.01). B. ATP levels of cells treated w
luminescent ATP assay. Mean±SD. (n=3; pb0.001). Cell viability was determined with
determined by monitoring ECAR using XF24 Extracellular Flux Analyzer. Arrow indicates thetomoxir (1 mM) for 30 minutes before dihydroethidine staining. We
ﬁrst analyzed the ROS level of SF188 cells and detected a substantial
increase in ﬂuorescence intensity. This suggests a signiﬁcant endog-
enous superoxide level present in SF188 control cells (Fig. 4A).
Etomoxir (1 mM) treatment of the cells resulted in a large increase in
ﬂuorescence intensity compared to the control untreated cells
indicating a greatly increased superoxide level (Fig. 4B). This ﬁnding
suggests that inhibition of fatty acid oxidation results in vastly
elevated ROS and therefore oxidative stress.
Increased intracellular ROS can result from increased production of
and/or a decreased elimination of ROS in cells. We, therefore,
investigated the antioxidant system which eliminates intracellular
ROS in SF188 cells. GSH in mitochondria and cytosol is a vital
antioxidant that eliminates ROS and defends cells against oxidative
stress and cell death [18,19]. The reducing equivalent NADPH is
required to regenerate GSH from the oxidized form G-S-S-G,
particularly in mitochondria, maintaining the GSH level [20,21]. We
tested the hypothesis that fatty acid oxidation in SF188 could provide
the substrate for NADPH production to maintain the GSH antioxidant
system. First, we evaluated the effect of etomoxir on the GSH level of
the cells. The cells plated in a microplate were treated with etomoxir
for 30 minutes in medium supplemented with 25 mM glucose and
6 mM glutamine and their GSH levels were measured by a
luminescent GSH assay. We observed that GSH level declines starting
at 0.75 mM etomoxir and 1 mM etomoxir decreased the GSH level to
approximately 50% relative to the control cells (Fig. 5A). This suggests
that inhibition of fatty acid oxidation compromised the GSH
antioxidant system of the cells.
Next, we determined the NADPH level in the cells treated with
etomoxir. The cells were harvested and suspended in medium
containing 25 mM glucose and 6 mM glutamine, then were treated
with etomoxir for 30 minutes and lysed for NADPH detection. The
NADPH level of each sample was determined using a ﬂuorescent
NADPH assay. We found that the NADPH level declined beginning at
0.75 mM etomoxir and to about 50% of the control at 1 mM etomoxir
(Fig. 5B) mirroring the etomoxir-induced decrease in GSH level in the
cells. This suggests that fatty acid oxidation can produce NADPH,
thereby providing the reducing equivalents to regenerate GSH in the
cells. The parallel declines of GSH and NADPH levels caused by
etomoxir treatment provide direct evidence to support the hypothesis
that oxidation of endogenous fatty acid can produce NADPH that may
protect cells from oxidative stress, ATP depletion and cell death. Given
that inhibition to fatty acid oxidation decreases NADPH, we also
sought to test whether the converse is true. Cells were pre-incubated
in DMEM containing palmitate–BSA for 1 hour before they were
harvested and lysed for NADPH detection.We found that NADPH level
increased by ~20% when palmitate–BSA was fed to the cells (Fig. 5C),
suggesting exogenously added fatty acids boosted cellular NADPHC
The number of viable cells was determined after treatment with etomoxir (1 mM) and
ith etomoxir (1 mM) and oligomycin (0.5 μM) for 45 minutes were determined using a
Calcein AM staining. C. Glycolysis responses to etomoxir or oligomycin (Oligo) were
e time when each compound was added.
Fig. 4. Inhibition of fatty acid oxidation elevated intracellular ROS level. A. Intracellular
superoxide level of SF188 cells was measured by dihydroethidine staining (shaded
histogram). Unstained cells were the control (open histogram). B. Intracellular
superoxide level was measured by dihydroethidine staining the cells after treatment
with 1 mM etomoxir (shaded histogram) and control (open histogram).
A
B
Fig. 6. Superoxide scavenger tiron rescues cellular ATP level but does not rescue fatty acid
oxidation.A. Cellular ATP levelswere determined after treatmentwith etomoxir (0.75 mM),
tiron (1 mM) and etomoxir in combination with tiron for 45 minutes. Mean±SD. (n=3;
pb0.001). B. Cellular oxygen consumption rate in response to etomoxir (0.75 mM) was
measured in the presence or absence of tiron (1 mM) in the medium. Arrow indicates the
time when each compound was added.
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leads to NADPH production and suggests that modulation of fatty acid
oxidation can control the NADPH level of the cells.
Since inhibition of fatty acid oxidation impairs the endogenous
antioxidant system causing ATP depletion and cell death as we
observed (section 3.3), we reasoned that supplementing the cells with
exogenous antioxidant during etomoxir treatment might restore the
antioxidant system and prevent ATP loss. We used tiron, a superoxide
scavenger, for this purpose. The cells were treated with 0.75 mM
etomoxir, 1 mM tiron and a combination of etomoxir and tiron for
45 minutes prior to ATP measurement. As shown in Fig. 6A, ATP level
was maintained in cells treated with tiron and etomoxir while in cells
treated with etomoxir, ATP level was reduced to ~60% of the control,
suggesting that tiron protected the cells fromATP depletion. Oxidative
damage to energy generation systems may, therefore, be the primary
cause of cellular ATP depletion which can be prevented by tiron. WeA B
Fig. 5. Inhibition of fatty acid oxidation causes depletion of GSH and NADPH level is modulate
for 30 minutes using a luminescent GSH assay. Mean±SD. (n=3; p=0.05). B. NADPH leve
30 minutes using a ﬂuorescent NADPH assay. Mean±SD. (n=3; pb0.05). C. NADPH level w
45 minutes. Cells fed with BSA was the control. Mean±SD. (n=3; pb0.01).also tested the antioxidant N-acetyl cysteine (NAC), a precursor of
glutathione, in preventing etomoxir-induced ATP depletion. In this
case, we did not ﬁnd a signiﬁcant effect (data not shown), suggesting
GSH loss most likely occurred due to an impaired ability to regenerate
GSH rather than an insufﬁcient supply of GSH precursor.
It can be argued that tiron may exert its protective effect by
restoring fatty acid oxidation. To exclude this possibility, we
examined the effect of tiron on etomoxir-induced inhibition of fatty
acid oxidation. Cellular oxygen consumption rate of the cells was
monitored in the medium containing 1 mM tiron before and after
0.75 mM etomoxir was added. We did not ﬁnd any signiﬁcant
difference between OCR of the cells in response to etomoxir in the
presence and absence of tiron (Fig. 6B). In other words, fatty acid
oxidation remained suppressed by etomoxir in the presence of tiron
while the ATP level was restored, strongly suggesting that the
etomoxir-induced NADPH decline and the resulting antioxidantC
d by fatty acid oxidation. A. GSH level was determined after treating cells with etomoxir
l was determined in cell lysate after treating the cells in suspension with etomoxir for
as determined in cell lysate after feeding the cells with palmitate–BSA (palm–BSA) for
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these results lend further support to our hypothesis that oxidative
stress resulting from NADPH deﬁciency causes ATP depletion.
Finally, we sought to test whether tiron could protect the cells
from etomoxir-induced death, similar to its ability to prevent ATP
depletion. Cells were treated with 0.75 mM etomoxir, 1 mM tiron and
a combination of etomoxir and tiron for 18 hours, and the number of
viable cells was determined. In contrast to the observed protection
against ATP loss, we observed minimal protection from etomoxir-
induced cell death by tiron compared to the control cells without tiron
(data not shown). This suggests that the impairment of the
antioxidant defense system that resulted from prolonged exposure
to etomoxir was extremely severe and the cell survival over an
extended period of time could not be rescued by tiron alone.
3.5. Etomoxir partially suppresses mitochondrial electron transport
system
It has reported that etomoxir increases oxidative stress in HepG2
cells [23], as we learned after the completion of this work. This raises
the possibility that etomoxir might have additional effects on
mitochondria in addition to blocking the transport of fatty acids. We
assessed whether etomoxir inhibits the mitochondrial electron
transport by measuring maximal respiration capacity using mito-
chondrial uncoupler FCCP in the presence or absence of etomoxir in
the presence of saturating concentrations of glucose, glutamine
pyruvate. The rationale of the experimental design is as follows.
FCCP uncouples electron transport from oxidative phosphorylation,
allowing maximal rate of electron transport under the condition of
unlimited electron supply (saturating substrate concentration), which
is reﬂected by maximal cellular oxygen consumption. If a compound,
for example etomoxir, inhibits the ETC, the FCCP-stimulated increase
in OCR would be less than that in the absence of an ETC inhibitor. We
used oligomycin, an inhibitor of ATP synthase but not the ETC, as aA
B
Fig. 7. Etomoxir partially suppresses mitochondrial electron transport chain. Etomoxir's
effect on the ETC was determined by sequential addition of etomoxir (0.5 mM) and
FCCP (0.3 μM) in SF188 cells (A) and C2C12 myocytes (B) in assay medium containing
glucose (25 mM), glutamine (6 mM for SF188 or 4 mM for C2C12) and pyruvate
(1 mM). A 0.3 μM FCCP is the concentration that stimulates maximal oxygen
consumption in both cell types determined in previous experiments. Mean±SD,
(n=4). Arrow indicates the time when each compound was added to cells in each well.negative control in the experiment; the FCCP-stimulated OCR increase
following oligomycin reﬂects maximal mitochondrial respired
capacity.
SF188 cells and C2C12 myocytes were used to test the effect of
etomoxir on the ETC. The cells were ﬁrst exposed to etomoxir (0.5 mM)
or oligomycin (1 μM) followed by FCCP (0.3 μM) in assay medium
containing 25 mM glucose, 6 mM (SF188) or 4 mM (C2C12) glutamine
and 1 mM pyruvate, which saturate the ETC as determined in separate
experiments (data not shown). Fig. 7 showed that FCCP-stimulatedOCR
increase following etomoxir addition is signiﬁcantly lower than after
oligomycin addition in both SF188 cells and C2C12 myocytes. The
smaller than expected OCR increase suggests that etomoxirmay restrict
the electron transport. We also used complex I inhibitor rotenone as a
positive control for ETC inhibition and found that FCCP completely failed
to stimulate OCR increase after rotenone addition (data not shown) in
both SF188 and C2C12myocytes. These results suggest that etomoxir, in
addition to blocking fatty acid transport into mitochondria, may
partially inhibit the electron transport chain. Hence, the observed
etomoxir effect on SF188 could be the sum of inhibition of fatty acid
oxidation and inhibition of the ETC.
4. Discussion
While moderate ROS levels promote cellular transformation and
cell proliferation, severe oxidative stress leads to cell death.
Intracellular ROS levels are controlled and balanced between ROS
production and elimination. The elimination of ROS is performed by
the antioxidant system, of which GSH is a central component [18,19].
GSH requires constant replenishment, and NADPH is essential in the
regeneration of GSH in the cellular defense against oxidative stress to
promote cancer cell growth and survival [20–22]. It is thought that
cellular NADPH for reductive biosynthesis is derived mainly from
glucose ﬂux through the pentose phosphate pathway and glutamine
ﬂux through the malic enzyme [4]. Our results suggest that NADPH
production fueled by mitochondrial fatty acid oxidation provides the
cells with an additional mechanism for producing the quantities of
NADPH needed to meet the demands of defense against oxidative
damage and cell death. This idea is further supported by our
observation that tiron prevents ATP depletion even though fatty
acid oxidation is not restored.
The fact that NADPH decrease occurs as a result of fatty acid
oxidation inhibition, even in the presence of glutamine and glucose,
suggests that NADPH production powered by these nutrients might
either be insufﬁcient or has a minimal impact on maintaining the
antioxidant system. Yuneve et al. [24] reported that glutamine
depletion-induced cell death in Myc-expressing human cells does
not involve an increase in ROS levels. Furthermore, oxidative stress is
not involved in apoptosis induced by glutamine depletion in those
cells, that is, tiron and NAC do not prevent cell death. These ﬁndings
could be interpreted as lack of glutamine involvement in antioxidant
defense of the cells. The present study supports and extends these
ﬁndings by demonstrating that fatty acid oxidation is a major source
of NADPH for defense against oxidative stress. Our results, therefore,
support a model in which fatty acids, rather than glutamine, serve as
the critical source of NADPH, particularly in the mitochondria, against
oxidative stress in rapidly proliferating Myc-dependent cells such as
SF188 where the oxygen consumption rate and ROS generation are
especially high. One explanation for glutamine's lack of prominence in
antioxidant defense could be that nearly all carbons derived from
glutamine exit a truncated TCA cycle and are exported into the
cytoplasm for fatty acid synthesis by two possible mechanisms.
Glutamine-derived malate and citrate (as reductive power and
building blocks) could either exit a forward-running truncated TCA
cycle prior to their conversion to isocitrate (Fig. 1A) [2] or exit a
backward-running TCA from α-KG to citrate as reportedly occurs in
brown adipocytes [25]. In other word, glutamine conversion to
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would be required to verify either scenario.
How could oxidative stress induced by inhibition of fatty acid
oxidation cause acute cellular ATP depletion? Mitochondrial ATP is
produced by oxidative phosphorylation and substrate level phos-
phorylation in the TCA cycle. TCA cycle enzymes such as aconitase and
α-ketoglutarate dehydrogenase (α-KDH) as well as the ETC com-
plexes are sensitive to ROS inactivation [26,27]. Mitochondria not only
generate ROS but are also major targets of ROS-induced oxidative
damage leading to severe harm to the TCA cycle enzymes and the ETC
complexes. Severe damages to the bioenergetic machinery would
result in a sharp decline in the mitochondrial ATP level, which is also
required for continuous glucose phosphorylation by mitochondria-
bound hexokinase in cancer cells [28]. Limited mitochondrial ATP
production would, therefore, impair glycolytic ATP synthesis. Dis-
abling both mitochondrial and glycolytic ATP production would cause
a catastrophic depletion of total cellular ATP and rapid cell death.
Tiron may temporarily protect key mitochondrial TCA cycle enzymes
and ETC complexes from ROS-induced inactivation, allowing contin-
uous ﬂux of NADH and ATP synthesis to proceed using glutamine
present in the medium while fatty acid oxidation is suppressed.
However, the data present here do not allow us to explain why tiron
did not prevent etomoxir-induced cell death. It is well-known that
excessive ROS can modify mitochondrial proteins that are involved in
cell death including the mitochondrial permeability transition pore
components voltage-dependent anion channel (VDAC) and/or the
adenine nucleotide translocase (ANT), and cardiolipin triggering cell
death [29]. It is conceivable that greatly increased intracellular ROS
that accumulates over hours of exposure to etomoxir damages these
proteins so severely that tiron alone cannot overcome it.
Although our study did not directly address the biochemical
pathways through which fatty acid oxidation fuels NADPH produc-
tion, two clues suggest that mitochondrial rather than cytosolic
NADPH production might be involved. Firstly, fatty acid oxidation
occurs within mitochondria. Secondly, tiron eliminates the superox-
ide radical O2− [30,31], which is the ﬁrst ROS generated in the
mitochondrial sequence. Therefore, tironmight eliminate ROS early to
minimize oxidative damage to the bioenergetics machinery and thus
prevent ATP loss induced by fatty acid oxidation inhibition. While
three enzymes contribute to cytosolic NADPH production in the cell,
only one enzyme, NADP+-dependent isocitrate dehydrogenase 2
(IDH2), can produce NADPH within the mitochondria. A number of
recent studies indicate that mitochondrial IDH2 is essential in
supplying the NADPH needed to defend cancer cells against
mitochondrial oxidative damage and promote cell survival [20–22].
For example, Jo et al. [16] has demonstrated that decreased expression
of IDH2 (IDPm) markedly elevates the ROS generation, lipid
peroxidation, DNA fragmentation and mitochondrial damage with a
signiﬁcant reduction in ATP level. However, genetic inactivation of
NADPH-producing enzymes such as IDH2 is still required to clearly
identify whether IDH2 is the responsible enzyme and whether the
cytosolic IDH1 (IDPc) is also involved in our model system.
Several lines of evidence indicate that intracellular lipid catabolism
is important for cancer cell growth and survival. First, monoacylgly-
cerol lipase, which catalyzes the release of fatty acid from intracellular
lipid, promotes tumor growth and survival [32]. Inhibition of this
enzyme reverses the process. Second, inhibition of fatty acid oxidation
reportedly sensitizes human leukemia cells to apoptosis induction by
BcL2 inhibitors [33]. Finally, fatty acid oxidation has been shown to be
associated with resistance to chemotherapeutic agents and radiation
and insensitivity to oxidative stress [34]. Our results—that fatty acid
oxidation produces NADPH to protect cells from oxidative stress and
death—are consistent with the importance of fatty acid catabolism in
promoting cancer cell growth and survival. We suggest that this fatty
acid oxidation-fueled NADPH production in protecting cells from
oxidative stress may be a common attribute of those rapidlyproliferating and highly oxidative cancer cells that results from
metabolic reprogramming by genetic alterations including Myc
ampliﬁcation. However, the present data do not allow us to discern
the relative contribution of each component, inhibition of fatty acid
oxidation or inhibition of electron transport, to the observed cellular
effects in SF188 cells. Genetic inactivation of CPT-1 is required to
address this.
In conclusion, our studies suggest that fatty acid oxidation may
provide a source of NADPH for regeneration of the GSH antioxidant
system and protects the cancer cells from oxidative damage, ATP
depletion and death. Our work also underscores the importance of
integrated mitochondrial metabolism, oxidative phosphorylation,
intermediary metabolism and redox balance in cancer cell growth
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